Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 4, 2006

Galapagos to Participate in Kidney Regeneration Consortium

  • Galapagos secured a E.U. grant of EUR500,000 for service division BioFocus DPI's participation in Proligen, a research consortium focused on enhancing regeneration of injured kidneys. The Proligen consortium, comprising a number of European companies and universities, aims to improve the regenerative capacity of injured kidneys, using information derived from genomics, proteomics, and functional genomics.

    Under the terms of the agreement, BioFocus DPI will use its SilenceSelect and FLeXSelect adenoviral libraries and cellular assay expertise to identify targets that can serve as starting points for the development of novel treatment methods for kidney injury. The resulting gene function information will provide the Proligen consortium the necessary tools to deliver new biologicals and cell-based therapies for kidney regeneration.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »